Analysts Have Made A Financial Statement On The Procter & Gamble Company's (NYSE:PG) Full-Year Report

Last week saw the newest yearly earnings release from The Procter & Gamble Company (NYSE:PG), an important milestone in the company's journey to build a stronger business. Revenues of US$87b were in line with forecasts, although statutory earnings per share (EPS) came in below expectations at US$6.62, missing estimates by 2.5%. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Taking into account the latest results, Procter & Gamble's 22 analysts currently expect revenues in 2027 to be US$88.7b, approximately in line with the last 12 months. Statutory per-share earnings are expected to be US$6.89, roughly flat on the last 12 months. In the lead-up to this report, the analysts had been modelling revenues of US$89.4b and earnings per share (EPS) of US$6.99 in 2027. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

See our latest analysis for Procter & Gamble

The analysts reconfirmed their price target of US$161, showing that the business is executing well and in line with expectations. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Procter & Gamble analyst has a price target of US$186 per share, while the most pessimistic values it at US$145. This is a very narrow spread of estimates, implying either that Procter & Gamble is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The period to the end of 2027 brings more of the same, according to the analysts, with revenue forecast to display 2.0% growth on an annualised basis. That is in line with its 2.3% annual growth over the past five years. Compare this with the broader industry (in aggregate), which analyst estimates suggest will see revenues grow 2.8% annually. So although Procter & Gamble is expected to maintain its revenue growth rate, it's forecast to grow slower than the wider industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at US$161, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Procter & Gamble analysts - going out to 2029, and you can see them free on our platform here.

Plus, you should also learn about the 1 warning sign we've spotted with Procter & Gamble .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.